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Synopsis  
Objectives: To describe trends in prevalence, susceptibility profile and risk factors for multi-drug 
resistant Neisseria gonorrhoeae (MDR-NG) in England and Wales. 
 
Methods: Isolates from 16,242 gonorrhoea episodes at sexual health clinics within the Gonococcal 
Resistance to Antimicrobials Surveillance Programme (GRASP) underwent antimicrobial susceptibility 
testing. MDR-NG was defined as resistance to ceftriaxone, cefixime, or azithromycin, PLUS ≥2 of: 
penicillin, ciprofloxacin, spectinomycin. Trends in resistance are presented for 2004-2015; 
prevalence and logistic regression analyses for MDR-NG cover the period of the most recent 
treatment guideline (ceftriaxone plus azithromycin), 2011-15. 
  
Results: Between 2004-2015, the proportion of NG isolates fully susceptible to all antimicrobial 
classes fell from 80%  to 46%, with the proportion resistant to multiple (two or more) classes 
increasing from 7.3% to 17.5%. In 2011-2015, 3.5% of isolates were MDR-NG, most of which were 
resistant to cefixime (100% in 2011, decreasing to 36.9% in 2015) and/or azithromycin (4.2% in 2011, 
increasing to 84.3% in 2015). After excluding azithromycin-resistant isolates, modal azithromycin 
MICs were higher in MDR versus non-MDR isolates (0.5 mg/L versus 0.125 mg/L), with similar results 
for ceftriaxone (modal MICs 0.03 mg/L versus ≤0.002 mg/L). After adjustment for confounders, 
MDR-NG was more common among isolates from heterosexual men, although absolute differences 
in prevalence were small (4.6% versus 3.3% (MSM) and 2.5% (women)). 
 
Conclusions: NG is becoming less susceptible to available antimicrobials. Since 2011, a minority of 
isolates were MDR-NG, however MICs of azithromycin or ceftriaxone (first line therapies) for many 
of these were elevated. These findings highlight the importance of continued antimicrobial 
stewardship for gonorrhoea.  
 
Introduction 
 
Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae (NG), is the second most commonly 
diagnosed bacterial Sexually Transmitted Infection (STI) in England.1 Although estimated prevalence 
in community settings in Britain is low (<0.1%),2 recent years have seen worrying increases in 
diagnoses among men who have sex with men (MSM).1,3 The history of rapid development of 
resistance to antimicrobials used for treatment has made antimicrobial resistant (AMR) NG a major 
global health concern and a priority area for Public Health England (PHE).4–9 Extended-spectrum 
cephalosporins (ESCs) are the most recent class of antimicrobial introduced to treat gonorrhoea, and 
represent a ‘last-line’ treatment option, with no new antimicrobials available and few in 
development.4,5,9,10 Since 2011, recommended first-line treatment in the UK has been dual therapy 
with 500 mg intramuscularly-injectable ceftriaxone (an ESC) plus 1 g oral azithromycin, in an attempt 
to prevent sustained resistance to ESCs becoming established,10,11 an approach which has been 
implemented in many other regions globally12. Although resistance to ceftriaxone is rare, recent 
increases in azithromycin resistance have been described, including high-level resistance.13,14 There 
is also evidence of N. gonorrhoeae becoming gradually less susceptible to ceftriaxone,15 and the first 
reported global case of dual treatment failure was also detected in the UK.16 Many have now 
highlighted that multi-drug resistant N. gonorrhoeae (MDR-NG) poses a serious threat, and 
untreatable gonorrhoea is an increasingly plausible prospect.5,7,9,10 
 
It is critical to understand the epidemiology of AMR NG to inform treatment guidelines and 
prevention and control measures, in addition to wider gonorrhoea prevention efforts.4,7,17 The 
Gonococcal Resistance to Antimicrobials Surveillance Project (GRASP) was established in 2000 to 
monitor trends and provide information on determinants of AMR NG in England and Wales,18 and 
combines susceptibility data with demographic, behavioural, and clinical information from those 
diagnosed with gonorrhoea at selected specialist sexual health services. GRASP has provided 
detailed insight into patterns of AMR in NG and informed changes to treatment guidelines.10,19 To 
date, GRASP data on trends and risk factors for individual antimicrobials have been reported,13,15,20,21 
but detailed analyses of MDR-NG have not. This project seeks to fill this knowledge gap by 
investigating the prevalence, resistance profile, and risk factors for MDR-NG in England and Wales in 
order to understand implications for the future treatment of gonorrhoea, and contribute to the 
scant epidemiological literature on MDR-NG.7,22–27  
 
Methods 
 
Ethics and governance 
PHE has permission to handle data obtained by GRASP under section 251 of the UK National Health 
Service Act of 2006, which was renewed annually by the ethics and confidentiality committee of the 
National Information Governance Board until 2013. Since then, the power of approval of public 
health surveillance activity has been granted directly to PHE. 
 
Data sources 
Detailed descriptions of GRASP methodology have been published previously.13 Briefly, isolates from 
individuals with gonorrhoea attending 27 specialist sexual health clinics in England and Wales during 
a three month period each summer between 2004 and 2015 were cultured and submitted to PHE for 
susceptibility testing. An agar dilution method was used to determine MICs for ceftriaxone, cefixime, 
spectinomycin, azithromycin, penicillin, and ciprofloxacin.  Susceptibility data were matched to 
demographic, clinical, and behavioural data submitted by the clinics. All patients diagnosed with 
gonorrhoea during this period were eligible for inclusion, however approximately half of episodes 
did not have susceptibility data due to culture not being attempted or successful.28  
 
Azithromycin MIC data 
The Diagnostic Sensitivity Test (DST) medium used for susceptibility testing for GRASP isolates was 
changed in 2015, whereupon MICs of azithromycin, and subsequently the proportion of resistant 
isolates, increased.13 A validation study compared the MICs determined by the new and old DST 
agars and found MICs of azithromycin were higher by approximately one dilution using the new DST 
medium. The new DST medium provided better pH and physiological conditions for growth of 
fastidious strains of N. gonorrhoeae which subsequently resulted in more reliable  azithromycin MIC 
determination; this was also confirmed by local quality assurance data.13 Azithromycin MIC data for 
2013 and 2014 (the years in which the problems with growth on the old DST medium were seen) 
were therefore adjusted upwards by a factor of one dilution to enable more accurate description of 
trends over time. 
 
Definition of MDR-NG 
Defining MDR-NG is challenging due to differences in first-line treatments over time and 
internationally. We therefore present analyses of i) patterns of AMR-NG over time, including 
resistance or decreased susceptibility to multiple classes of antimicrobials, to facilitate international 
and longer-term comparisons; ii) MDR-NG defined as relevant to current clinical practice in the UK. 
For the latter, we adapted the working definition proposed by Tapsall et al (2009): resistance or 
decreased susceptibility to one or more antimicrobial in widespread use to treat gonorrhoea 
(category 1), and resistance to two or more antimicrobials in less frequent use/little use but 
proposed for more frequent use (category 2).7 The original Tapsall definition included spectinomycin 
in category 1, and azithromycin in category 2; we updated this based on currently recommended 
therapies in the UK (table 1). Although cefixime has not been recommended for treatment of NG 
since 2011, we retained it in category 1 as it is an ESC.  
Descriptive and statistical analyses 
Descriptive analyses were used to examine trends in AMR NG for 2004-2015. Analysis of MDR-NG 
was restricted to 2011 onwards, to reflect prevalence and risk factors relevant to current treatment 
guidelines. Modal ceftriaxone and azithromycin MICs were compared between MDR and non-MDR 
isolates to assess whether there was a drift towards resistance to first-line therapies in MDR-NG 
among those not yet resistant to these antimicrobials. As resistance to ceftriaxone or azithromycin is 
included in the definition of MDR-NG, these sub-analyses excluded all isolates which already had 
decreased susceptibility to ceftriaxone (for comparison of ceftriaxone MICs) or resistance to 
azithromycin (for comparison of azithromycin MICs). For the risk factor analysis, logistic regression 
was used to generate Odds Ratios (ORs) initially adjusted for year, age (as a quadratic term, to 
account for the non-linear relationship) and gender/sexual orientation (groupings: MSM, 
heterosexual men, all women). Associations with the following variables were examined: ethnicity, 
residential neighbourhood-level Index of Multiple Deprivation (IMD), number of recent sexual 
partners (past 3 months), recent sex abroad (past 3 months), previous gonorrhoea infection, 
symptomatic infection, clinician-coded site of infection, concurrent STIs, and HIV status. 
Multivariable logistic regression analyses were used to determine independent associations, using a 
forwards model-building approach, with variables retained in the final model based on a p-value 
≤0.10. Exploratory analysis showed evidence of within-clinic (but not within-patient) clustering of 
MDR-NG, i.e. there was greater similarity in MDR-NG between isolates collected within the same 
clinic than at different clinics. To avoid this resulting in underestimated standard errors, clustering 
was accounted for in the risk factor analysis using Generalised Estimating Equations under the 
assumption of an exchangeable correlation matrix.29  
 
 
Results  
 
Sample characteristics 
Between 2004 and 2015, 16,242 isolates from 15,781 patients underwent susceptibility testing, with 
47.4% of isolates from MSM, 28.2% from heterosexual men, and 20.6% from women 
(supplementary table 1).  
 
Patterns of antimicrobial resistance in GRASP 2004-2015 
Resistance to azithromycin was generally low until 2012 (<5%), then increased to 9.8% in 2015 
(figure 1). Decreased susceptibility to ceftriaxone was rare (0.1%), whereas levels of decreased 
susceptibility to cefixime increased rapidly between 2008 and 2010 (from 3% to 17%), then 
decreased to 1.1% in 2015 (figure 1). Resistance to penicillin and ciprofloxacin was widespread 
(>10%) throughout the study period. 
 
Between 2004 and 2015, the proportion of NG isolates fully susceptible to all classes of 
antimicrobials fell from 80% to 46%, with the proportion resistant to multiple (two or more) classes 
increasing from 7.3% to 17.5% (figure 2). Resistance to three classes increased between 2008 and 
2010 then declined, mirroring trends in cefixime resistance (figure 1, figure 2). A small number of 
isolates were resistant to all four classes tested (n=49; 0.3% overall).  
 
Despite high levels of susceptibility to prevailing first-line therapies immediately following revisions 
to treatment guidelines in 2005 (from ciprofloxacin to cefixime)30 and 2011 (to ceftriaxone and 
azithromycin dual therapy)11, the proportion of isolates fully susceptible to first-line therapies 
declined in the following years, from 99.9% in 2005 to 82.9% in 2010, and from 99.5% in 2011 to 
90.2% in 2015 (figure 3). 
 
Prevalence and profile of MDR-NG 
Between 2011 and 2015, 3.5% (n=266) of isolates were MDR-NG, with small increases in prevalence 
between 2011 and 2013 (from 3.7% to 4.5%) followed by a subsequent decrease to 2.2% in 2015 
(chi-squared test p=0.004). The profile of resistance to category 1 antimicrobials among MDR-NG 
isolates changed over time: 100% were resistant to cefixime in 2011, reducing to 36.9% in 2015, with 
increases in the proportion resistant to azithromycin over this time frame from 4.2% to 84.3% 
(p<0.01) (figure 4). All MDR-NG isolates were resistant to both ciprofloxacin and penicillin, but not 
spectinomycin, in category 2. Over time, the proportion of MDR-NG resistant to four antimicrobials 
(cefixime, azithromycin, penicillin, and ciprofloxacin) increased from 4.2% in 2011 to 21.1% in 2015. 
One isolate had resistance/decreased susceptibility to five antimicrobials: ceftriaxone (MIC 0.125 
mg/L), cefixime (MIC 0.25 mg/L), azithromycin (MIC 1.0 mg/L), ciprofloxacin (MIC ≥16 mg/L), and 
penicillin (MIC 1 mg/L).  
 
In a sub-analysis excluding all isolates with resistance to azithromycin, the MICs of azithromycin for 
MDR isolates were elevated (modal MIC 0.5 mg/L) compared with those for non-MDR isolates 
(modal MIC 0.125 mg/L) (figure 5a). Similarly, after excluding isolates with ceftriaxone decreased 
susceptibility, modal ceftriaxone MICs for MDR isolates were higher (0.03 mg/L) than those for non-
MDR isolates (≤0.002 mg/L) (figure 5b). The elevated ceftriaxone MICs among MDR isolates were 
observed in a further sub-analysis stratified by year (grouped as 2011-13 (n=176 MDR isolates) and 
2014-15 (n=87 MDR isolates)); ceftriaxone modal MIC of 0.03 mg/L among MDR isolates versus 
0.004 mg/L among non-MDR isolates in both time periods.  
 
Risk factors for MDR-NG  
MDR-NG was more common among heterosexual men than MSM or women (4.6% versus 3.3% and 
2.5%, respectively); these differences remained significant after adjustment for other factors (Table 
2). Multivariable analysis also found MDR-NG to be more common among isolates from older 
patients (Adjusted Odds Ratio for those aged ≥45 years: 1.89 [95% Confidence Interval: 1.25-2.86], 
compared with those aged ≤24 years) and those reporting recent sex abroad (AOR 1.38 [95% CI: 
1.02-1.87]), and less common among isolates from patients who were of black Caribbean ethnicity 
(AOR 0.26 [95% CI 0.47-0.87]), were HIV positive (AOR 0.64 [0.47-0.87]), or had a concurrent STI 
(AOR 0.77 [0.61-0.97]). Neighbourhood deprivation (IMD) data were not available in GRASP for 2011 
therefore IMD was not included in the multivariable model, however a separate multivariable model 
run on 2012-2015 data found no association between MDR-NG and IMD after adjustment for other 
factors. 
 
Discussion 
 
Our data demonstrate increases in antimicrobial resistance of N. gonorrhoeae over the past decade 
in England and Wales, with the proportion of NG isolates fully susceptible to all classes of 
antimicrobials falling from 80% in 2004 to 46% in 2015, and the proportion resistant to two or more 
classes increasing from 7.3% to 17.5% over this period. Despite high levels of susceptibility to 
recommended treatments immediately following changes to treatment guidelines in 2005 and 2011, 
the proportion fully susceptible to these decreased in a matter of years. In 2011-2015, 3.5% of 
isolates were classed as MDR-NG, meaning they were resistant to either azithromycin or an 
extended spectrum cephalosporin, as well as to penicillin and ciprofloxacin. In 2011, MDR-NG 
isolates were predominantly resistant to cefixime, however, by 2015 the majority were resistant to 
azithromycin, with around one in five resistant to both. We also found evidence of drift towards 
azithromycin resistance among MDR-NG isolates that were not resistant to azithromycin, and similar 
drift towards ceftriaxone resistance. The fact that these elevated ceftriaxone MICs in the MDR 
isolates were observed in 2014-15 as well as 2011-13 suggests this finding is unlikely to be solely due 
to the cefixime-resistant ST1407 strains which also have elevated ceftriaxone MICs and were 
prevalent during 2011-2013.25 Although the risk factor analysis found MDR-NG was more common 
among isolates from some groups, including heterosexual men and older patients, absolute 
differences in prevalence were small, providing little basis for targeted treatment strategies. These 
findings highlight the importance of continued surveillance and prevention efforts, given the 
severely limited treatment options available to those with MDR-NG. 
 
Advantages to using the GRASP surveillance data include the large sample size, ability to look at 
trends over time, and to combine MIC data with demographic, clinical, and behavioural information. 
GRASP is  reasonably representative of gonorrhoea cases across England, although MSM are 
somewhat overrepresented.31 It is likely that risk characteristics of MSM and heterosexual sexual 
networks differ, but small numbers of MDR-NG prohibited stratification of risk factor analysis by 
gender/sexual orientation. Another limitation is the potential for missing data to bias results of the 
risk factor analysis; for example completion of behavioural data varied by clinic resulting in more 
missing data for MSM.  Azithromycin MIC data from 2013-14 were adjusted to account for poor 
organism growth using DST media which underestimated MICs. This adjustment enabled 
comparisons of AMR over time, but is a crude correction and some misclassification is likely. 
 
In line with low levels of resistance to ceftriaxone generally,13 few MDR-NG cases had decreased 
susceptibility to ceftriaxone. However, MICs of ceftriaxone have been drifting towards resistance in 
recent years,15 leaving no room for complacency about the long-term effectiveness of current dual 
therapy. Our analysis found that the ceftriaxone MICs for MDR-NG isolates were  higher than for 
non-MDR isolates, after excluding those with decreased susceptibility to ceftriaxone, demonstrating 
how easily MDR-NG with resistance to ceftriaxone could emerge and lead to infections which would 
be difficult to treat.  Although all isolates were susceptible to spectinomycin, this is not considered a 
viable first-line treatment as resistance has historically developed rapidly when it has been used, it is 
not effective in treating pharyngeal gonorrhoea, and it is currently unavailable in many countries.5 It 
should be borne in mind that 96.5% of isolates were not MDR, which is promising in light of efforts 
to develop point-of-care AMR testing to guide treatment choices.32 If successful, such tests could 
identify infections for which previously-used therapies would be effective, reducing ceftriaxone use 
and the selection pressure for resistance.   
 
Despite commentaries on the emerging threat of MDR-NG,5,6,33 the international literature on 
prevalence and risk factors is scant, perhaps due to lack of consensus on an MDR definition, 
preventing comparison of prevalence and risk factors.22,23,26 In general the risk factors for MDR-NG 
identified here are consistent with those associated with resistance to some individual 
antimicrobials in previous studies, including being a heterosexual man (ciprofloxacin, azithromycin, 
cefixime),34 the inverse relationships with black Caribbean ethnicity (ciprofloxacin, cefixime),20,21 and 
concurrent STI infection (ciprofloxacin, cefixime).20,21 However, previous analyses of GRASP data 
have found a positive association between HIV and NG that was resistant to cefixime, ciprofloxacin, 
penicillin,20,21 in contrast with the inverse relationship with MDR-NG found here. Continued 
monitoring of the epidemiology of MDR-NG alongside resistance to individual antibiotics is therefore 
needed. 
 
These data emphasise the loss of susceptibility of NG to sequential antimicrobial classes used for 
treatment, and provide the first prevalence estimates of MDR-NG in England and Wales. Although 
prevalence of MDR-NG was relatively low, many of these isolates were resistant to azithromycin and 
had ceftriaxone MICs that were higher than for non-MDR isolates. In the context of limited new 
treatment options, the emergence of ceftriaxone resistance in MDR-NG could herald the prospect of 
untreatable NG. MDR-NG was generally homogenously distributed by demographic and behavioural 
characteristics, with no groups identified as being at especially high risk, highlighting the need for 
continued culture and susceptibility testing and test of cure among all patients with gonorrhoea. Our 
findings underline the essential role of timely surveillance to identify and respond to clinically 
significant changes in AMR NG in the coming years.  
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Tables and figures 1 
 2 
Table 1: Category of antibiotic and MIC thresholds used to define resistance or decreased susceptibility in 3 
GRASP 4 
 5 
 6 
GRASP standard breakpoints.13 Decreased susceptibility, rather than ‘resistance’ is used in GRASP for ESCs as treatment failures have 7 
been observed across a range of MIC values in some patients but not others. 8 
 9 
 10 
  11 
Category 1 antibiotics: MIC breakpoint for resistanceR or decreased susceptibilityDS 
CeftriaxoneDS >0.06 mg/L 
CefiximeDS >0.06 mg/L 
AzithromycinR >0.5 mg/L 
Category 2 antibiotics:  
CiprofloxacinR >0.5 mg/L 
PenicillinR >0.5 mg/L or β-lactamase positive 
SpectinomycinR >64 mg/L 
 
Figure 1: Percentage of Neisseria gonorrhoeae isolates with antimicrobial resistance/decreased susceptibility, 12 
by year, England and Wales, GRASP 2004–2015 (n=16242)   13 
 14 
Note: Azithromycin data for 2013-14 adjusted to account for poor growth on the DST medium leading to 15 
underestimation of azithromycin MIC in those years (See Methods for further details). 16 
 17 
This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. 18 
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Figure 2: Percentage of Neisseria gonorrhoeae isolates resistant to 0, 1, 2, 3, or 4 classes of antimicrobials, by 20 
year, England and Wales, GRASP 2004–2015 (n=16242)    21 
 22 
 23 
 24 
Classes of antimicrobials: a) extended-spectrum cephalosporin (cefixime & ceftriaxone) b) macrolide 25 
(azithromycin)  c) fluoroquinolone (ciprofloxacin) d)  penicillin e) aminoglycoside (spectinomycin). 26 
a 2013-14 estimates calculated using adjusted azithromycin data. 27 
 28 
This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. 29 
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Figure 3: Percentage of isolates fully susceptible to recommended first-line therapy a England and Wales, 32 
GRASP 2004–2015 (n=16242)   33 
  34 
a Recommended first-line therapies: ciprofloxacin (2004), cefixime (2005-2010), ceftriaxone and azithromycin (2011-2015).  35 
b Azithromycin data for 2013-14 adjusted to account for poor growth on the DST medium leading to underestimation of 36 
azithromycin MIC in those years (see Methods for further details). 37 
 38 
This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. 39 
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Figure 4: Resistance/decreased susceptibility to category 1a antimicrobials among MDR-NG isolates over time, 41 
England and Wales, GRASP 2011–2015 (n=266)      42 
 43 
 44 
a Category 1 antimicrobials: Ceftriaxone, Cefixime, Azithromycin; category 2 antimicrobials: ciprofloxacin, penicillin, 45 
spectinomycin. See methods for further details. 46 
All MDR-NG isolates were resistant to ciprofloxacin and penicillin in category 2. 47 
 48 
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Figure 5: Distribution of MICs for a) azithromycin and b) ceftriaxone among MDR-NG and non-MDR-NG 51 
isolates not meeting the resistance/decreased susceptibility thresholds for ceftriaxone/azithromycin 52 
respectively. England and Wales, 2011–2015    53 
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Table 2: Risk factors for MDR-NG among Neisseria gonorrhoeae isolates, England and Wales, GRASP 2011-2015 
  
  
Total 
N 
    
Adjusted for age, year, and 
gender/sexual orientation 
Multivariable model 
(n=4027) 
  n % AOR1 (95% CI) AOR2 (95% CI) 
  
            
All 7562 266 3.5%         
Year       p=0.04 p<0.001 
2011 1288 48 3.7% ref   ref   
2012 1375 57 4.1% 1.16 (0.76 - 1.66) 1.16 (0.72 - 1.88) 
2013 1636 74 4.5% 1.26 (0.77 - 2.08) 3.86 (2.51 - 5.94) 
2014 1564 49 3.1% 0.84 (0.62 - 1.14) 3.61 (2.43 - 5.37) 
2015 1699 38 2.2% 0.64 (0.36 - 1.11) 0.60 (0.35 - 1.03) 
Gender/sexual orientation       p=0.02 p=0.05 
Heterosexual men 1571 72 4.6% ref   ref   
MSM 4683 156 3.3% 0.67 (0.45 - 1.01) 0.76 (0.57 - 0.99) 
Women 1123 28 2.5% 0.62 (0.42 - 0.90) 0.66 (0.44 - 0.99) 
Age group       p=0.13 p=0.01 
≤24 2337 64 2.7% ref   ref   
25-44 4507 173 3.8% 1.42 (0.98 - 2.03) 1.35 (1.01 - 1.81) 
≥45 714 29 4.1% 1.49 (0.96 - 2.29) 1.89 (1.25 - 2.86) 
Ethnicitya       p=0.01 p=0.004 
White 5187 197 3.8% ref   ref   
Black Caribbean 580 12 2.1% 0.42 (0.21 - 0.81) 0.26 (0.47 - 0.87) 
Black African 281 7 2.5% 0.55 (0.25 - 1.19) 0.87 (0.43 - 1.76) 
Black Other 180 5 2.8% 0.63 (0.24 - 1.66) 0.27 (0.04 - 1.78) 
Asian (including Chinese) 360 15 4.2% 1.04 (0.53 - 2.06) 1.58 (0.79 - 3.14) 
Mixed Ethnic Group 500 13 2.6% 0.63 (0.30 - 1.32) 0.75 (0.35 - 1.62) 
Other Ethnic Group 181 5 2.8% 0.64 (0.25 - 1.63) 1.00 (1.02 - 1.87) 
Patient's area-level deprivation 
(IMD) quintile       p=0.09 
    
1 or 2 (least deprived) 698 34 4.9% ref       
3 835 26 3.1% 0.63 (0.42 - 0.93)     
4 1974 70 3.5% 0.71 (0.49 - 1.04)     
5 (most deprived) 2341 73 3.1% 0.59 (0.37 - 0.96)     
Number of sexual partners (past 3 
months)       p>0.99     
0-1 1974 71 3.6% ref       
 
2-5 3021 112 3.7% 0.99 (0.72 - 1.38)     
>6 845 30 3.6% 1.00 (0.60 - 1.69)     
Sex while abroad (past 3 months)       p=0.03 p=0.04 
No 5170 175 3.4% ref   ref   
Yes 670 38 5.7% 1.55 (1.04 - 2.30) 1.38 (1.02 - 1.87) 
Previous gonorrhoea infection       p=0.69     
No 4440 159 3.6% ref       
Yes 2325 77 3.3% 0.95 (0.72 - 1.25)     
Symptoms of gonorrhoeab       p=0.68     
No 1810 59 3.3% ref       
Yes 4241 162 3.8% 1.07 (0.78 - 1.46)     
Clinicial-coded site of infectionc               
Genital       p=0.87     
No 1848 69 3.7% ref       
Yes 4644 167 3.6% 0.88 (0.62 - 1.25)     
Rectal       p=0.49     
No 4027 155 3.8% ref       
Yes 2480 81 3.3% 0.90 (0.68 - 1.20)     
Throat       p=0.06     
No 4517 154 3.4% ref       
Yes 1990 82 4.1% 1.43 (0.98 - 2.09)     
Other       p=0.67     
No 6338 229 3.6% ref       
Yes 169 7 4.1% 1.31 (0.73 - 2.34)     
Multiple sites of infection       p=0.76     
No 4353 160 3.7% ref       
Yes 2154 76 3.5% 1.06 (0.72 - 1.57)     
Concurrent STI (excl HIV)       p=0.01 p=0.03 
No 5639 219 3.9% ref   ref   
Yes 1923 47 2.4% 0.66 (0.48 - 0.90) 0.77 (0.61 - 0.97) 
HIV status       p=0.002 p=0.005 
Negative 3592 141 3.9% ref   ref   
Positive 1264 31 2.5% 0.52 (0.34 - 0.78) 0.64 (0.47 - 0.87) 
 
AOR1=Adjusted Odds Ratio, adjusted for  year, age (quadratic), gender/sexual orientation.  AOR2=Multivariable model, adjusted for 
other variables shown. Age adjusted for as a quadratic variable, but AORs and p-value presented for age group for ease of 
interpretation.   
a IMD was not available for 2011 in GRASP; b Discharge/painful urination (dysuria); c Sites not mutually-exclusive. Where patient had 
multiple infection sites, this site may not correspond to the site that underwent susceptibility testing as only one isolate per patient was 
included in GRASP. Isolates were prioritised as follows: 1) Male Rectal 2) Male Urethral 3) Female Cervical 4) Any other site. 
 
 
